CG
IOVA icon

Cutler Group’s Iovance Biotherapeutics IOVA Stock Holding History

Cutler Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1K Sell
5,100
-15,900
-76% -$185K ﹤0.01% 2028
2023
Q4 		$36K Buy
+21,000
New +$110K ﹤0.01% 1639
2023
Q1 		– Sell
-4,200
Closed -$1K – 4246
2022
Q4 		$1K Sell
4,200
-18,400
-81% -$144K ﹤0.01% 4047
2022
Q3 		$6K Sell
22,600
-1,400
-6% -$16.1K ﹤0.01% 3506
2022
Q2 		$33K Sell
24,000
-57,400
-71% -$752K ﹤0.01% 2258
2022
Q1 		$99K Buy
81,400
+50,100
+160% +$775K 0.01% 1713
2021
Q4 		$8K Sell
31,300
-21,800
-41% -$480K ﹤0.01% 3860
2021
Q3 		$41K Sell
53,100
-19,300
-27% -$455K ﹤0.01% 2672
2021
Q2 		$158K Buy
72,400
+45,400
+168% +$1.18M 0.01% 1511
2021
Q1 		$12K Sell
27,000
-6,200
-19% -$257K ﹤0.01% 3649
2020
Q4 		$163K Buy
33,200
+29,100
+710% +$1.16M 0.01% 1210
2020
Q3 		$9K Sell
4,100
-31,800
-89% -$975K ﹤0.01% 3073
2020
Q2 		$17K Sell
35,900
-11,400
-24% -$375K ﹤0.01% 2503
2020
Q1 		$173K Buy
47,300
+37,800
+398% +$1M 0.01% 1038
2019
Q4 		$57K Sell
9,500
-5,400
-36% -$123K ﹤0.01% 1544
2019
Q3 		$6K Buy
14,900
+9,900
+198% +$219K ﹤0.01% 2920
2019
Q2 		$13K Buy
+5,000
New +$75.3K ﹤0.01% 2489
2018
Q4 		– Sell
-10,000
Closed -$4K – 4231
2018
Q3 		$4K Buy
+10,000
New +$142K ﹤0.01% 3174
2018
Q2 		– Sell
-14,200
Closed -$42K – 4507
2018
Q1 		$42K Sell
14,200
-1,300
-8% -$19.7K ﹤0.01% 1779
2017
Q4 		$12K Buy
15,500
+13,100
+546% +$105K ﹤0.01% 2982
2017
Q3 		$2K Sell
2,400
-23,200
-91% -$147K ﹤0.01% 5087
2017
Q2 		$33K Buy
25,600
+22,800
+814% +$145K ﹤0.01% 2903
2017
Q1 		$4K Sell
2,800
-10,900
-80% -$79.9K ﹤0.01% 4898
2016
Q4 		$8K Buy
13,700
+13,100
+2,183% +$90.1K ﹤0.01% 4428
2016
Q3 		$1K Buy
+600
New +$5.08K ﹤0.01% 6148
2016
Q2 		– Sell
-5,500
Closed -$5K – 6938
2016
Q1 		$5K Sell
5,500
-4,500
-45% -$24.6K ﹤0.01% 4833
2015
Q4 		$11K Buy
+10,000
New +$69.4K ﹤0.01% 4035

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cutler Group's IOVA Position: Q1 2024 in Review

Cutler Group opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2024: 2,397 shares worth $35K. The stake represents 0.01% of the portfolio and ranks #807 among its holdings. This is a return to the name: Cutler Group previously reported a position in IOVA as recently as Q3 2023.

Cutler Group first reported a position in IOVA in Q4 2015 and has held it in 23 quarters since. The position peaked at $1M in Q3 2021. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

  • Cutler Group held 2,397 shares of Iovance Biotherapeutics worth $35K as of Q1 2024.
  • Iovance Biotherapeutics was a new Cutler Group position in Q1 2024.
  • Iovance Biotherapeutics made up 0.01% of Cutler Group's portfolio in Q1 2024, its #807 holding.
  • Cutler Group first reported a position in Iovance Biotherapeutics in Q4 2015 and has held it in 23 quarters since.
  • Cutler Group's Iovance Biotherapeutics position peaked at $1M in Q3 2021.
  • 273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.